GlucoModicum today published a peer-reviewed article highlighting key insights into its non-invasive glucose biosensor technology. Helsinki, Finland-based GlucoModicum published its findings in Biosensors and Bioelectronics. The company said it highlights key features of the development of ultra-sensitive electrochemical glucose biosensors. Its work reflects efforts in engineering and system-level design, forming the basis of the company’s product […]
GlucoModicum
GlucoModicum unveils Sofio needle-free CGM
GlucoModicum today unveiled Sofio, which it labels the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD). MHD technology draws micro-samples of interstitial fluid through the skin. It measures glucose with established electrochemical sensor technology. The single-day sensor system delivers a periodic, personalized monitoring alternative to standard continuous glucose monitor (CGM) devices. Helsinki, Finland-based GlucoModicum’s […]
GlucoModicum has positive data for needle-free CGM
GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose monitor (CGM). Helsinki, Finland-based GlucoModicum said in a news release that the study helps put the company on “a clear path to commercialization.” The study involved 646 participant visits, including individuals with type 2 diabetes and healthy volunteers. The company […]
Phillips-Medisize, GlucoModicum partner on needle-free CGM
Molex company Phillips-Medisize today announced a partnership with GlucoModicum to design a new continuous glucose monitor (CGM). The companies teamed up to design and eventually commercialize a proprietary, non-invasive, wearable CGM device. They aim to remove the technology and patient-care roadblocks that exist within continuous glucose monitoring. Phillips-Medisize develops drug delivery, in vitro diagnostic and […]
